Arthur Pougnant

TKIs currently used for bronchopulmonary cancer treatment target the epidermal growth factor receptor (EGFR). EGFR is a transmembrane receptor involved in tumor development which is overexpressed in most Non-Small Cell Lung Cancer (NSCLC) tumors. It has been found that soluble isoforms of EGFR are synthesized by both normal and NSCLC cells. Here, we wonder if these soluble isoforms could have an impact on the response to TKIs. To find out, we will compare the response to TKIs treatment of transfected NSCLC cells overexpressing soluble isoforms of EGFR with regular NSCLC cells. Viability, proliferation and migration will be observed.